The Federal Circuit’s recent decision to uphold a Patent Trial and Appeal Board ruling that dietary supplement patents licensed by Merck KGaA are invalid as obvious illustrates the many risks for patents in inter partes reviews as well as the difficulty of overturning PTAB decisions on appeal.
The Federal Circuit's affirmance also provides a clear picture of the deference that the appeals court is giving the board in AIA reviews on factual issues like secondary considerations.
IP associate David Soofian noted that given such findings are subject to deference on appeal, they will be harder to overturn, adding in that “the standard of review can make or break a case."
Also of Interest
- On the Road to a Safe and Secure Internet of Things: What Companies Should Do September 19, 2016 • Articles
- Consumer Products: Adapting to Innovation Fall 2016 • Reports / Newsletters
- UNITED STATES: Trade Facilitation and Trade Enforcement Act of 2015 Strengthens... August 23, 2016 • Articles
- UNITED STATES: Phantom Mark Depicting Arrangement of Numerical Financial Data... August 23, 2016 • Articles
- Daily Journal Names Malecek Among the “Top 75 Intellectual Property Litigators” August 17, 2016 • Recognitions
- Best Lawyers 2017 Recognizes 41 Kaye Scholer Lawyers August 15, 2016 • Recognitions
- Kaye Scholer Secures Complete Motion to Dismiss for Redwood Capital July 22, 2016 • Client Successes
- NISPOM’s New Insider Threat Program Is an Opportunity to Establish Competitive Edge July 13, 2016 • Client Alerts
- Kaye Scholer Represents NexPhase Capital in Acquisition of Zing Zang July 7, 2016 • Client Successes